Serologic determinants of survival in patients with head and neck cancer: validating a clinical prediction model.
Quantitative measurements of serum C1q-binding macromolecules (C1qBM) and immunoglobulin A (IgA) were done on 162 patients using previously described methodology. The measurements were compared to a previously described head and neck cancer population. Using the Cox Proportional Hazards model, the prognostic implications regarding high C1qBM and subsequent death with disease (P = .02), and regional recurrence (P = .0094) were validated, but not our previous IgA-related prognostic implications. When both study populations were combined, C1qBM was predictive of survival in those patients treated with induction chemotherapy (P = .0001). C1qBM was not a significant predictor of survival in patients treated with surgery plus postoperative radiation therapy in either this second "test" population or in the original "training" population. The findings demonstrate the confounding influence of treatment modalities and the importance of model validation.
Lydiatt
D D
DD
Department of Head and Neck Surgery, University of Texas M. D. Anderson Cancer Center, Houston.
Savage
H E
HE
Clayman
G L
GL
Liu
F J
FJ
Sample
D
D
Schantz
S P
SP
D000367:Age Factors; D014408:Biomarkers, Tumor / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000473:pathology / Q000556:secondary / Q000628:therapy; D002352:Carrier Proteins / Q000097:blood*; D015922:Complement C1q / Q000032:analysis*; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D006258:Head and Neck Neoplasms / Q000097:blood* / Q000473:pathology / Q000628:therapy; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood*; D008297:Male; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011971:Receptors, Immunologic / Q000032:analysis*; D015996:Survival Rate; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D007070:Immunoglobulin A; D011971:Receptors, Immunologic; D015922:Complement C1q